Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis
-
Published:2021-11
Issue:
Volume:
Page:
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Rodriguez-Vida AlejoORCID,
Rodríguez-Alonso Andrés,
Useros-Rodríguez EduardoORCID,
Lopez-Campos FernandoORCID,
Amor-Carro Oscar,
Arribas-Ruiz Alberto,
Martinez-Torres JavierORCID,
Roca-Pardiñas Javier,
Quesada-García Alba,
Muñoz-Del-Toro Jacobo R.ORCID,
Juárez-Soto ÁlvaroORCID
Reference30 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial;Duchesne;Lancet Oncol,2016
3. Managing nonmetastatic castration-resistant prostate cancer;Mateo;Eur Urol,2019
4. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial;Saad;Lancet Oncol,2018
5. Metastases-free survival rate in non-metastatic castration-resistant prostate cancer: now living on its own! [Article in Spanish];Juárez-Soto;Actas Urol Esp,2019
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献